Bioscan

What Bioscan does

Bioscan is a Washington, DC-based private medical diagnostic equipment company founded in 1980 that develops instrumentation for the detection, synthesis, and imaging of radio-labeled compounds. Its commercial product portfolio is centered on the VitalScan platform, a suite of FDA-cleared, non-invasive diagnostic systems for autonomic nervous system (ANS) testing, vascular assessment, and sudomotor function evaluation. The core technology combines Bioelectric Impedance Analysis (BIA) with Quantitative Sudomotor Axon Reflex Test (QSART) methodology, achieving 80% sensitivity and 95% specificity for neuropathy detection. The portfolio includes modular add-ons (Combo Pro+, ANS+, ANS Tilt, SudoCheck+, Vascular+, ABI+) and complementary sub-brands covering EEG, ECG, cognitive assessment, sleep diagnostics, and athletic performance.

The company operates a sales-led go-to-market model, selling diagnostic equipment directly to healthcare providers including general practitioners, cardiologists, neurologists, and pain medicine specialists. Revenue derives from one-time/perpetual license sales of capital equipment, with multi-year contracts and quote-based pricing. Distribution channels include direct sales, phone ordering, and a regional distributor network with a "Become Our Distributor" program. Bioscan has raised approximately $3.3 million in disclosed funding across four rounds (2005-2011), with Brook Venture Partners as the sole identified institutional investor. The company is led by founder and CTO Seth Shul and CFO Dennis Rosatelli. The target use cases focus on early detection of conditions such as cardiac autonomic neuropathy, diabetic autonomic neuropathy, small fiber neuropathy, vascular abnormalities, orthostatic hypotension, syncope, and hypertension risk, with results delivered in approximately 15 minutes per test.

Name

Bioscan

Website

https://bioscan.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

Bioscan develops FDA-cleared, non-invasive diagnostic equipment (VitalScan ANS, SudoCheck, vascular systems) for autonomic nervous system and neuropathy screening, sold to healthcare providers including cardiologists, neurologists, and general practitioners.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Autonomic Disorders (Dysautonomia) (HLAKAIAN)

Keywords

• Medical diagnostic equipment
• Autonomic nervous system testing
• Sudomotor function testing
• Vascular assessment systems
• FDA-cleared diagnostics

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Diagnostic Equipment Sales: Sale of FDA-cleared diagnostic testing equipment to healthcare providers including hospitals, clinics, and physician practices. Equipment includes VitalScan ANS System, SudoCheck System, and vascular assessment products.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Bioscan develops, manufactures, and sells FDA-cleared non-invasive medical diagnostic equipment (under the VitalScan brand) that enables healthcare providers to assess autonomic nervous system function, vascular health, and sudomotor function within approximately 15 minutes. Core products include the VitalScan ANS System for autonomic function testing and the SudoCheck System for peripheral neuropathy and sudomotor evaluation, with modular add-ons for vascular, ABI, and tilt-table assessment. Sales are conducted to general practitioners, cardiologists, neurologists, and pain medicine specialists through direct sales, phone ordering, and regional distributors.

Product overview

Bioscan (VitalScan) offers a comprehensive diagnostic product portfolio built around the VitalScan platform—a unified FDA-cleared system for non-invasive autonomic nervous system, vascular, and sudomotor assessment. The core VitalScan ANS System serves as the central diagnostic platform, with modular add-ons including VitalScan Combo Pro+ (multi-modality testing), VitalScan ANS+ and ANS Tilt (autonomic function variants), VitalScan SudoCheck+ and SudoCheck System (sudomotor/sweat gland evaluation), VitalScan Vascular+ (arterial assessment), and VitalScan ABI+ (peripheral vascular testing). The portfolio also includes branded partner products: BrainView NS Pro+ (cognitive/neurological), NeuroTrace EEG (brain activity), CardioView ECG (cardiac monitoring), SleepStudy PSG (sleep diagnostics), and QAthlete (athletic performance). Tests are completed in approximately 15 minutes and provide immediate interpretive reports for clinical screening.

Differentiator

Problem solved

Functional benefit

Products and services

• VitalScan ANS System FDA-cleared non-invasive diagnostic system for testing autonomic nervous system function, providing comprehensive autonomic function testing, cardiovascular fitness assessment, and health risk factor identification within 15 minutes. Targets physicians treating patients at risk for sudden death, silent heart attack, hypertension, cardiac autonomic neuropathy, diabetic autonomic neuropathy, vascular abnormalities, orthostatic hypotension, and syncope.
• SudoCheck System Clinical sudomotor testing system evaluating sweat gland function through galvanic skin response combined with QSART (Quantitative Sudomotor Axon Reflex Test) for early detection of diabetic neuropathy, painful diabetic neuropathy, and autonomic disorders, with 80% sensitivity and 95% specificity. Used by general practitioners, cardiologists, neurologists, and pain medicine specialists for cardiometabolic risk screening.
• VitalScan Combo Pro+ Comprehensive diagnostic system combining multiple testing modalities for autonomic, vascular, and sudomotor assessment, intended for clinicians who require integrated multi-modality screening in a single platform.
• VitalScan ANS Tilt Autonomic function testing system with tilt table capability for orthostatic and postural assessment, used to evaluate orthostatic hypotension, POTS (Orthostatic Tachycardia Syndrome), and related autonomic disorders.
• VitalScan Vascular+ Vascular assessment system providing pulse wave velocity, arterial stiffness, endothelial function testing, and segmental vascular assessment for cardiovascular risk evaluation.
• VitalScan ABI+ Ankle-Brachial Index testing system for peripheral vascular disease screening, delivering ABI measurements for clinicians evaluating arterial insufficiency and vascular abnormalities.

Quantifiable outcome

• 15-minute diagnostic testing for autonomic nervous system function
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• GE HealthCare: GE HealthCare offers broad patient monitoring, ECG, and vascular assessment platforms (e.g., MAC, CARESCAPE) used in cardiology and critical care; it competes with VitalScan in vascular and cardiovascular diagnostics as part of a much larger multi-modality portfolio.
• Masimo: Masimo is a leading patient monitoring and pulse oximetry company whose Rainbow SET platform captures SpO2, perfusion index, and PVi signals used in autonomic and vascular assessment, overlapping with VitalScan's SpO2 and PAT capabilities as part of a broader monitoring franchise.
• Philips Healthcare: Philips provides integrated cardiology and patient monitoring solutions (including ECG and vascular modules) that overlap with VitalScan's cardiovascular and ANS testing in hospital and ambulatory settings, though Philips does not specialize in autonomic/sudomotor diagnostics.
• Omron Healthcare: Omron Healthcare is a major manufacturer of blood pressure monitors, vascular screening devices, and home health equipment sold into primary care and pharmacy channels; it competes with VitalScan in vascular and cardiovascular risk assessment at a broader, more consumer-oriented scale.

Direct peers

• Compumedics: Compumedics manufactures clinical EEG, PSG, and neurological diagnostic systems (including the Somfit and E-Series lines) that overlap with the SleepStudy PSG and NeuroTrace EEG products distributed alongside VitalScan in sleep and neurology practices.
• WR Medical Electronics (WR Test): WR Medical produces the QSWEAT / Q-Sweat Quantitative Sudomotor Axon Reflex Test system, the historical gold-standard QSART device referenced on VitalScan's product pages, making it a direct competitor in clinical sudomotor and small fiber neuropathy testing.
• ImpediMed: ImpediMed develops bioimpedance spectroscopy (BIS) devices for fluid status and body composition, using a core bioimpedance technology stack closely related to Bioscan's BIA-based sudomotor assessment, and addresses similar clinician segments (cardiologists, diabetologists, oncology).
• Medeia: Medeia is the corporate entity associated with the VitalScan product line (per the vitalscan.com site branding), making it either a parent, affiliate, or the closest corporate peer for the Bioscan-branded portfolio.
• Itamar Medical: Itamar Medical (acquired by ZOLL/Asahi Kasei) makes the WatchPAT and EndoPAT devices for autonomic function and peripheral arterial tone assessment, directly competing with VitalScan in cardiovascular autonomic and endothelial testing for cardiologists and sleep specialists.
• Natus Medical: Natus Neuro provides clinical neurodiagnostic and autonomic testing equipment (including EMG, EEG, and related neurophysiology tools) that overlaps with the BrainView NS Pro+ and NeuroTrace EEG sub-brands in Bioscan's portfolio, serving neurologists and sleep specialists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/TrifoilImaging
• LinkedInlinkedin.com/company/trifoil-imaging

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioscan